This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Evans, D. B. Articles by Wolff, R. A. Search for Related Content PubMed PubMed Citation Articles by Evans, D. B. Articles by Wolff, R. A. Related Articles Related Articles Related Editorial Social Bookmarking                            What's this?

Preoperative Gemcitabine-Based Chemoradiation for Patients With Resectable Adenocarcinoma of the Pancreatic Head

Douglas B. Evans, Gauri R. Varadhachary, Christopher H. Crane, Charlotte C. Sun, Jeffrey E. Lee, Peter W.T. Pisters, Jean-Nicolas Vauthey, Huamin Wang, Karen R. Cleary, Gregg A. Staerkel, Chusilp Charnsangavej, Elizabeth A. Lano, Linus Ho, Renato Lenzi, James L. Abbruzzese, Robert A. Wolff

From the Departments of Surgical Oncology, Gastrointestinal Medical Oncology, Radiation Oncology, Gynecologic Oncology, Pathology, and Diagnostic Imaging, The University of Texas M.D. Anderson Cancer Center, Houston, TX

Corresponding author: Douglas B. Evans, MD, Department of Surgical Oncology, Unit 444, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030; e-mail: devans{at}mdanderson.org

Purpose We conducted a phase II trial to assess the outcomes of patients who received preoperative gemcitabine-based chemoradiation and pancreaticoduodenectomy (PD) for stage I/II pancreatic adenocarcinoma.

Patients and Methods Eligible patients with pancreatic head/uncinate process adenocarcinoma and radiographically defined potentially resectable disease received chemoradiation with 7 weekly intravenous (IV) infusions of gemcitabine (400 mg/m² IV over 30 minutes) plus radiation therapy (30 Gy in 10 fractions over 2 weeks). Patients underwent restaging 4 to 6 weeks after completion of chemoradiation and, in the absence of disease progression, were taken to surgery.

Results The study enrolled 86 patients. At the time of restaging, disease progression or a decline in performance status precluded 13 patients from surgery. Seventy-three (85%) of 86 patients were taken to surgery, extrapancreatic disease was found in nine, and 64 (74%) of 86 underwent a successful PD. Median overall survival (86 patients) was 22.7 months with a 27% 5-year survival. Median survival was 34 months for the 64 patients who underwent PD and 7 months for the 22 unresected patients (P < .001). The 5-year survival for those who did and did not undergo PD was 36% and 0%, respectively.

Conclusion Preoperative gemcitabine-based chemoradiation followed by restaging and evaluation for surgery separated the study population into two different subsets: patients likely to benefit from PD (n = 64) and those in whom surgery would be unlikely to provide clinical benefit (n = 22). Furthermore, the encouraging overall survival observed in this large trial supports the continued investigation of gemcitabine-based preoperative therapy in resectable pancreatic cancer.

Supported by the Various Donor Fund, the Lockton Fund for Pancreatic Cancer Research at The University of Texas M.D. Anderson Cancer Center, and Eli Lilly & Co.

Presented in part at the 38th Annual Meeting of the American Society of Clinical Oncology, May 18-21, 2002, Orlando, FL.

Authors’ disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

Related Articles

• Preoperative Gemcitabine and Cisplatin Followed by Gemcitabine-Based Chemoradiation for Resectable Adenocarcinoma of the Pancreatic Head
  Gauri R. Varadhachary, Robert A. Wolff, Christopher H. Crane, Charlotte C. Sun, Jeffrey E. Lee, Peter W.T. Pisters, Jean-Nicolas Vauthey, Eddie Abdalla, Huamin Wang, Gregg A. Staerkel, Jeffrey H. Lee, William A. Ross, Eric P. Tamm, Priya R. Bhosale, Sunil Krishnan, Prajnan Das, Linus Ho, Henry Xiong, James L. Abbruzzese, and Douglas B. Evans
  JCO 2008 26: 3487-3495 [Abstract] [Full Text]
• Analysis of Fluorouracil-Based Adjuvant Chemotherapy and Radiation After Pancreaticoduodenectomy for Ductal Adenocarcinoma of the Pancreas: Results of a Large, Prospectively Collected Database at the Johns Hopkins Hospital
  Joseph M. Herman, Michael J. Swartz, Charles C. Hsu, Jordan Winter, Timothy M. Pawlik, Elizabeth Sugar, Ray Robinson, Daniel A. Laheru, Elizabeth Jaffee, Ralph H. Hruban, Kurtis A. Campbell, Christopher L. Wolfgang, Fariba Asrari, Ross Donehower, Manuel Hidalgo, Luis A. Diaz, Jr, Charles Yeo, John L. Cameron, Richard D. Schulick, and Ross Abrams
  JCO 2008 26: 3503-3510 [Abstract] [Full Text]
• Adjuvant Radiotherapy and Chemotherapy for Pancreatic Carcinoma: The Mayo Clinic Experience (1975-2005)
  Michele M. Corsini, Robert C. Miller, Michael G. Haddock, John H. Donohue, Michael B. Farnell, David M. Nagorney, Aminah Jatoi, Robert R. McWilliams, George P. Kim, Sumita Bhatia, Matthew J. Iott, and Leonard L. Gunderson
  JCO 2008 26: 3511-3516 [Abstract] [Full Text]

Related Editorial

• Past and Future of Pancreas Cancer: Are We Ready to Move Forward Together?
  Nipun Merchant and Jordan Berlin
  JCO 2008 26: 3478-3480 [Full Text]

This article has been cited by other articles:

				N. A. van der Gaag, E. A.J. Rauws, C. H.J. van Eijck, M. J. Bruno, E. van der Harst, F. J.G.M. Kubben, J. J.G.M. Gerritsen, J. W. Greve, M. F. Gerhards, I. H.J.T. de Hingh, et al. Preoperative Biliary Drainage for Cancer of the Head of the Pancreas N. Engl. J. Med., January 14, 2010; 362(2): 129 - 137. [Abstract] [Full Text] [PDF]

				T. Okazaki, M. Javle, M. Tanaka, J. L. Abbruzzese, and D. Li Single Nucleotide Polymorphisms of Gemcitabine Metabolic Genes and Pancreatic Cancer Survival and Drug Toxicity Clin. Cancer Res., January 1, 2010; 16(1): 320 - 329. [Abstract] [Full Text] [PDF]

				R. Le Scodan, F. Mornex, N. Girard, C. Mercier, P.-J. Valette, M. Ychou, F. Bibeau, P. Roy, J.-Y. Scoazec, and C. Partensky Preoperative chemoradiation in potentially resectable pancreatic adenocarcinoma: feasibility, treatment effect evaluation and prognostic factors, analysis of the SFRO-FFCD 9704 trial and literature review Ann. Onc., August 1, 2009; 20(8): 1387 - 1396. [Abstract] [Full Text] [PDF]

				X. Dong, L. Jiao, Y. Li, D. B. Evans, H. Wang, K. R. Hess, J. L. Abbruzzese, and D. Li Significant Associations of Mismatch Repair Gene Polymorphisms With Clinical Outcome of Pancreatic Cancer J. Clin. Oncol., April 1, 2009; 27(10): 1592 - 1599. [Abstract] [Full Text] [PDF]

				N. Merchant and J. Berlin Past and Future of Pancreas Cancer: Are We Ready to Move Forward Together? J. Clin. Oncol., July 20, 2008; 26(21): 3478 - 3480. [Full Text] [PDF]

				G. R. Varadhachary, R. A. Wolff, C. H. Crane, C. C. Sun, J. E. Lee, P. W.T. Pisters, J.-N. Vauthey, E. Abdalla, H. Wang, G. A. Staerkel, et al. Preoperative Gemcitabine and Cisplatin Followed by Gemcitabine-Based Chemoradiation for Resectable Adenocarcinoma of the Pancreatic Head J. Clin. Oncol., July 20, 2008; 26(21): 3487 - 3495. [Abstract] [Full Text] [PDF]